Insider Selling: CeriBell (NASDAQ:CBLL) CEO Sells 3,372 Shares of Stock

CeriBell (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 3,372 shares of the business's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $15.03, for a total value of $50,681.16. Following the sale, the chief executive officer now owns 743,079 shares of the company's stock, valued at $11,168,477.37. The trade was a 0.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Wednesday, April 23rd, Xingjuan Chao sold 15,628 shares of CeriBell stock. The shares were sold at an average price of $15.11, for a total transaction of $236,139.08.
• On Thursday, April 17th, Xingjuan Chao sold 5,700 shares of CeriBell stock. The shares were sold at an average price of $15.02, for a total value of $85,614.00.

CeriBell Price Performance

Shares of NASDAQ CBLL traded up $0.41 during mid-day trading on Thursday, reaching $15.49. 359,258 shares of the company traded hands, compared to its average volume of 273,059. CeriBell has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The company has a fifty day moving average of $19.78.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million during the quarter, compared to analyst estimates of $17.55 million. Sell-side analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CBLL. Legal & General Group Plc acquired a new stake in shares of CeriBell in the fourth quarter worth about $32,000. Summit Investment Advisors Inc. bought a new stake in CeriBell during the fourth quarter worth approximately $33,000. Tower Research Capital LLC TRC acquired a new position in CeriBell during the fourth quarter valued at approximately $37,000. BNP Paribas Financial Markets bought a new position in shares of CeriBell in the fourth quarter valued at approximately $43,000. Finally, PNC Financial Services Group Inc. acquired a new stake in shares of CeriBell in the fourth quarter worth $47,000.

Wall Street Analyst Weigh In

Several analysts recently weighed in on CBLL shares. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a report on Wednesday, February 26th. LADENBURG THALM/SH SH assumed coverage on CeriBell in a research note on Friday, April 4th. They set a "buy" rating and a $32.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, CeriBell presently has an average rating of "Buy" and an average price target of $32.50.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.